Business
Extension of warrants in Incanthera plc
Extension of warrants in Incanthera plc.
About this update from Immupharma Plc
[{"type":"text","content":"\n\n\n 21 August 2023\n \nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\n \n \nExtension of Warrants in Incanthera plc\n \nImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed with Incanthera plc (\"Incanthera\") that Warrants issued to the Company on 26 February 2020, in conjunction with Incanthera's IPO onto the Aquis Exchange, are extended by 12 months.\n \nKey highlights:\n \n· The Company entered into a Warrant Instrument (\"Warrant Instrument\") with Incanthera on 26 February 2020, whereby Incanthera created and issued Warrants to ImmuPharma to subscribe in cash at £0.095 per share, for 7,272,740 Ordinary Shares, valid until 6 September 2023.\n \n· Incanthera has agreed with the Company to extend the Warrant Instrument by 12 months to 6 September 2024.\n \n· All other provisions in the Warrant Instrument remain the same.\n \n· No consideration is being paid by ImmuPharma to obtain the extension.\n \nImmuPharma currently owns 9,904,319 shares in Incanthera (representing 12.7% of its issued share capital). In addition, Tim McCarthy, ImmuPharma's Chairman, is also the Chairman of Incanthera and has a holding of 3,931,646 shares (5.05%).\n&n...